Home > Insider Trading > Filing (0000950142-10-000391)

Filing Details

Accession Number:: 0000950142-10-000391
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-08 12:00:00
Reporting Period:: 2010-03-04

Filing Date:: 2010-03-08
Accepted Time:: 2010-03-08 20:50:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1401923	Map Pharmaceuticals Inc.	MAPP	Pharmaceutical Preparations (2834)	200507047

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1237655	Sfm Ah Llc	888 Seventh Avenue 31St Floor New York NY 10106		No	No	Yes	No
1253598	Sfm Participation Lp	888 Seventh Avenue 31St Floor New York NY 10106		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-03-04	97	$14.09	2,861,970	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-04	677	$14.15	2,861,970	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-04	3,061	$14.15	2,861,970	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-05	6,524	$13.95	2,829,958	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-05	4,616	$13.95	2,829,958	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-05	20,872	$13.95	2,829,958	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.00 to $14.23. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, SFM Participation, L.P ("SFM Participation"), a managing member of Perseus-Soros Partners, and Biotech Management Partners, LLC ("Biotech Management Partners"). SFM Participation is a managing member of Biotech Management Partners. SFM AH, LLC ("SFM AH"), is the general partner of SFM Participation.
Represents 97 shares of the Issuer's Common Stock sold by SFM Participation. After the sale SFM Participation owns directly 10,313 shares of the Issuer's Common Stock.
Represents 677 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners owns directly 4,616 shares of the Issuer's Common Stock.
Represents 3,061 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale Biotech Management Partners owns directly 20,872 shares of the Issuer's Common Stock.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $13.70 to $14.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Represents 6,524 shares of the Issuer's Common Stock sold by SFM Participation. After the sale SFM Participation owns directly 3,789 shares of the Issuer's Common Stock.
Represents 4,616 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners directly owns no shares of the Issuer's Common Stock.
Represents 20,872 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale Biotech Management Partners directly owns no shares of the Issuer's Common Stock.